Company intelligence / Profile preview

EOC Pharma

Taizhou or Shanghai*, Jiangsu Sheng, Chinaeocpharma.com ↗

Ownership: Private
Development stage: Other

Overview

EOC Pharma has a pipeline focused on oncology with at least one drug approved in China and others in late-stage clinical development. The company specializes in the development and commercialization of innovative cancer therapies for the Chinese market. Its lead programs include both small molecule inhibitors and immunotherapies licensed from global partners. Notably, it holds exclusive rights to develop Immutep’s eftilagimod alpha (a soluble LAG3 protein) for the Chinese market.

Therapeutic areas: Oncology
Modalities: Small moleculesbiologics (including immunotherapies such as LAG3 modulators)
Industry: Biotech

Partnerships

Immutep Ltd. (eftilagimod alpha licensing)Bayer AG (originator of telatinib)

Beyond the preview

Go deeper on EOC Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EOC Pharma.